Biotech Patent Due Diligence: 7 Checks Before a Deal

Biotech patent due diligence is the review that decides whether a target’s revenue is durable or about to fall off a cliff. In pharmaceuticals, a product’s sales are only as protected as the patents and FDA exclusivities that wall it off from generics and biosimilars — and the industry is entering its steepest loss-of-exclusivity wave in a generation. EY estimates US$356 billion of branded sales are at risk from patent expiration between 2023 and 2028, and analysts call it the largest cliff since 2010. If your valuation model extrapolates today’s revenue past the date the patents expire, you are not buying a growth story — you are buying a cliff. Here are seven checks that separate the two.

What Biotech Patent Due Diligence Actually Measures

Generic M&A diligence confirms that patents exist, are in force, and belong to the seller. Biotech patent due diligence has to answer a harder question: for how many more years can the target legally exclude competitors from each product, and how much of the purchase price depends on that answer? Because a drug’s revenue is a direct function of its right to exclude, the cliff date is the valuation.

Single-asset dependence sharpens the risk. Merck’s Keytruda alone generated about $29.5 billion in 2024 — roughly 56% of the company’s business — with core US patents expiring in 2028. Most acquisition targets are smaller versions of the same shape: a large share of value sitting in one or two products whose protection runs out on a specific, findable date. The job of diligence is to find that date and test how solid the wall really is.

Check 1: Map Revenue to the Patents That Cover It

Start by tying each material product to the specific patents and claims that read on the marketed form — composition of matter, formulation, method of use, and manufacturing process — rather than accepting the target’s patent-count summary. Only claims that cover the commercial product protect the revenue; a thick portfolio around a discontinued indication protects nothing.

This mapping is where inflated valuations quietly deflate. A target may report a decade of runway on the strength of a headline patent family, when the composition-of-matter patent that actually blocks generics expires far sooner. Map revenue to claims first, and every later check has a much smaller, sharper set to examine.

Check 2: Build the Orange Book Exclusivity Timeline

For small molecules, pull every patent listed in the FDA’s Orange Book for the product, with each expiry date, plus the regulatory exclusivities layered on top — new chemical entity, orphan, and any pediatric extension. The Orange Book is the map a generic must navigate under the Hatch-Waxman framework, so it is also the map that dates the visible cliff.

For biologics, the Orange Book does not apply. Build the timeline from the 12-year reference-product exclusivity under the Biologics Price Competition and Innovation Act (BPCIA) and check the Purple Book for licensed biosimilars. Small-molecule and biologic products on the same balance sheet run on different clocks and must be diligenced on separate tracks.

Check 3: Test Paragraph IV and Biosimilar Exposure

A listed patent is not a strong patent. Search for Abbreviated New Drug Application (ANDA) Paragraph IV certifications challenging the target’s patents, and test whether any 30-month Hatch-Waxman litigation stay is live. A Paragraph IV challenge against a weak formulation patent can bring a generic to market years before the patent’s stated expiry — collapsing the cliff forward into your ownership period.

The speed of the fall matters as much as the timing. EY documents franchises meeting nine generic entrants at once on loss of exclusivity; price and share do not erode gently, they drop. For biologics, model the realistic biosimilar-entry date from filings and the BPCIA “patent dance,” not the patent’s face-value expiry.

Check 4: Find the Unlisted Process Patents

The Orange Book is the start of diligence, not the end. Process and manufacturing patents frequently sit outside it entirely, and they cut both ways. On the upside, a manufacturing-process patent the seller never marketed can genuinely complicate cost-effective generic entry, adding real protection to the asset you are buying.

On the downside, an unlisted third-party process patent can block the target’s own next-generation program. A freedom-to-operate sweep for unlisted patents is the only way to surface both — hidden protection you are paying too little for, and hidden blocking rights you would otherwise inherit as a surprise. This is standard practice in a rigorous IP due diligence workflow.

Check 5: Pressure-Test Validity With IPR and Prior Art

Assess the key patents for validity risk, not just existence. An inter partes review (IPR) at the USPTO’s Patent Trial and Appeal Board can invalidate the very patent a valuation rests on, and a serious prior-art problem is a repricing event, not a footnote. Pull the docket on any pending Paragraph IV or IPR proceeding that could accelerate loss of exclusivity.

The output you want is not a yes/no on each patent but a probability-weighted cliff: the date protection most likely ends once challenges, stays, and biosimilar timelines are modelled against the listed expiries. That is the number a deal model should discount.

Check 6: Trace Chain of Title and Licences

Confirm the target actually owns what it is selling. Trace assignments from each named inventor, check for gaps that break the chain of title, and read every in-licence for scope. University licences are common in biotech and often carry field-of-use limits, milestone obligations, and Bayh-Dole march-in rights that constrain what an acquirer can do with the asset.

These defects are cheap to find in diligence and expensive to discover after closing. A single missing confirmatory assignment or an overlooked field-of-use restriction can strand a pipeline program the buyer thought it had acquired outright.

Check 7: Price the Cliff Into the Deal

Biotech patent due diligence earns its keep at the negotiating table. Model the dated cliff, the Paragraph IV exposure, and the biosimilar timeline against the target’s straight-line projection, and the difference between reported revenue and protected revenue becomes a concrete percentage of enterprise value at risk — a number you can put in the model and defend to a board.

Acquirers rarely need to walk. When diligence surfaces a datable risk, they restructure: earn-outs contingent on a Paragraph IV outcome, specific IP representations and warranties, IP insurance, or confirmatory assignments as conditions to closing, so each risk sits with the party best able to bear it. For the same wave viewed from the seller’s side, see our pharma patent cliff analysis.

From Checklist to a Worked Example

These seven checks are the method; the value is in how they change a specific number. In our biotech IP due diligence case study, the same sequence exposed a lead asset whose composition-of-matter patent expired in 2028, a formulation patent softer than it looked, and a process patent worth more than the seller was marketing — and repriced the deal accordingly.

Whether you are acquiring a single-asset biotech or a diversified portfolio, the discipline is the same: separate today’s revenue from the years of protected revenue behind it, and pay for the second number. In the largest loss-of-exclusivity wave since 2010, nothing else in the diligence pack matters more.

Diligencing a Biotech or Pharma Target?

PerspireIP runs IP due diligence that maps a target’s revenue to the patents and regulatory exclusivities that actually protect it, dates every cliff, and prices the gap between reported and protected revenue — before you sign. See the method applied end to end in our biotech IP due diligence case study.

Frequently Asked Questions